细胞因子诱导的杀伤细胞治疗急性白血病的研究进展

细胞因子诱导的杀伤（CIK）细胞是在体外用白细胞介素2、肿瘤坏死因子γ以及CD3单抗刺激外周血单个核细胞而获得的一组异质细胞群（CD3 ＋CD56 ＋）,其增殖能力和细胞毒活性都较高.其不但可逆转部分白血病细胞的多药耐药现象,还可能对G0期的瘤细胞有效.一些临床Ⅰ～Ⅱ期试验已经证实了CIK细胞治疗急性白血病的有效性和安全性.另外,临床上为进一步提高CIK细胞的疗效,还应用了一些辅助治疗方法（如白细胞介素2和树突状细胞等）.CIK细胞内在抗肿瘤的生物学机制与免疫系统的相互作用仍有待进一步研究,以期进一步提高治疗急性白血病的效果.

The Research Progress of the Use of Cytokine-induced-killer Cells in the Treatment for Acute Leukemia

CIK cells （CD3^＋ CD56^＋ ） are generated from peripheral blood mononuclear cells which are activated by IL-2 （interleukin-2）,IFN-γ（ interferon-γ）, and anti-CD3-antibody in vitro. These ceils have a high proliferation power and a high anti-tumor activity. The muhidrug resistance of some tumor cells may be reversed by using CIK cells. Moreover,CIK cells may have a potential of killing tumor ceils in Go stage. In some phase Ⅰ - Ⅱ clinical trials, the efficacy and safety of CIK have been affirmed in the treatment of acute leukemia. The treatment using IL-2 or dendritic ceils is always considered as an adjuvant therapy used to increase the treatment effect of CIK. The interaction between CIK cells（which have its biological mechanism of anti-tumor activity） and immune system still needs to be investigated to improve the therapeutic effect for aeute leukemia.